Table 2.
Treatment characteristics at the time of recurrence, dose–volume parameters (DVH) at the time of the initial definitive treatment and number of events based on the type of treatment for recurrent disease
| Variable | CHT (n = 25) | CHT +BEV (n = 10) |
|---|---|---|
| Fistulae | ||
| Total | 2 (8%) | 4 (40%) |
| Rectovaginal | 2 | 1 |
| Vesicovaginal | 0 | 3 |
| Mean (SD) no. of treatment cycles | ||
| CHT cycles | 5.1 (1.9) | 6.4 (4.5) |
| BEV cycles | – | 5.4 (3.6) |
| BT application type | ||
| IC | 4 | 0 |
| IC/IS | 21 | 10 |
| Radiation dose (Gy) | ||
| Mean D90 HRCTV | 90.4 (7.6) | 89.4 (5.7) |
| Mean D0.1cc rectum | 73.5 (11.3) | 73.1 (8.5) |
| Mean D2cc rectum | 63.6 (7.7) | 63.4 (6.9) |
| Mean D0.1cc sigmoid | 78.0 (13.9) | 80.0 (7.2) |
| Mean D2cc sigmoid | 64.7 (7.8) | 66.7 (5.8) |
| Mean D0.1cc bladder | 100.3 (13.3) | 100.5 (7.7) |
| Mean D2cc bladder | 79.8 (8.4) | 82.4 (6.0) |
| Mean D0.1cc bowel | 58.5 (29.5) | 65.4 (37.4) |
| Mean D2cc bowel | 52.6 (26.3) | 55.1 (30.1) |
CHT chemotherapy, BEV bevacizumab, BT brachytherapy, HRCTV high-risk clinical target volume, D90 dose to 90% of the HRCTV, SD standard deviation, IC intracavitary only, IC/IS intracavitary and interstitial brachytherapy, D2cc dose to 2cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder)